Author: admin

  • 5 new Apple products we won’t see at the Apple Event 2025

    5 new Apple products we won’t see at the Apple Event 2025

    Apple fans only have a few more days to wait for the Apple Event 2025, aka the official launch of the iPhone 17, which is slated for Sept. 9. Typically, Apple also uses this event to launch other products as well. For instance, last year’s event featured the iPhone 16, the Apple Watch Series 10, AirPods 4, and more. That will likely remain true this year as well, but not everything in Apple’s rumored pipeline is set to make its debut next week. 

    Before we get started, let’s recap the stuff we expect to see at Apple’s release event this year. That includes the iPhone 17, the Apple Watch Series 11, the Apple Watch Ultra 3, the ultra-thin iPhone 17 Air, and likely the AirPods Pro 3. For these Apple September launch events, the company typically sticks to the iPhone, AirPods, and Apple Watch, but there are a few other products expected in 2025 that could sneak their way into the event. 

    However, there are even more new Apple products we’re not expecting to see at the event, either because Apple will have a separate event for them later in 2025 or because they won’t be available until 2026.

    The next iPhone ‘e’ model

    Apple replaced the iPhone SE with the iPhone ‘e’ model phones starting with the iPhone 16e. While it is nice to see Apple treating its affordable iPhone with the same deference as the main models, we don’t think Apple will launch the next ‘e’ iPhone alongside the iPhone 17. There are several reasons for this, but in short, the next affordable iPhone will almost certainly be in absentia come Sept. 9. 

    The main reason for this is that Apple typically saves those releases for spring, and this dates back to the iPhone SE models. Apple’s first SE model was launched in March 2016, and the second and third generations were launched in April 2020 and March 2022, respectively. Apple continued this trend with the iPhone 16e, which was launched in February 2025. It seems likely that an iPhone 17e is coming next year, per Mark Gurman of Bloomberg. 

    New Mac products

    Apple is reportedly working on several new Mac products, including an M4 Mac Pro and, of course, Mac computers with the upcoming M5 chip that Apple is no doubt working on. Generally speaking, Apple saves its Mac announcements for a separate event that usually takes place in either October or May, depending on the product and the launch. So, if you need a new MacBook laptop, you still have some time to wait. 

    Those announcements may even have to wait until 2026. The upcoming MacBook Pro with an M5 chip is rumored to be delayed until 2026, along with several other products. Thus, in short, we won’t see any new Mac products at the iPhone launch next week, and we may not see some of them until 2026 at all. The M4 Mac Pro might still come out before the end of 2026, though. 

    Mashable Light Speed

    New iPads

    Much like the Mac products, Apple generally saves new iPad announcements for other events, usually alongside the Mac products. In the recent past, Apple has saved iPad announcements for springtime, and we have no reason to believe Apple will stray from tradition and announce any early with the iPhone 17. 

    Per Gurman, Apple is definitely saving its iPad announcements for early 2026. The products may include a new low-end iPad, new iPads with M4 chips, and the aforementioned iPhone 17e as part of a “flurry of new products” landing in the first half of next year. In any case, don’t expect any iPads at the September Apple Event 2025.

    New AirPods Max

    The AirPods Pro 3 are on the docket for an announcement (we think), but the AirPods Max aren’t. The first generation is already pretty old, at around five years, and it seems the next generation of the AirPods Max is still pretty far out. Apple is keeping the next generation under wraps until 2027, per MacRumors, which is very, very far away from next week. 

    The update will be a welcome one. Rumor suggests that the next generation will be lighter, introduce new technology like heart rate monitoring, and updated internals. Apple did refresh the AirPods Max last year, but the refresh only added new color options and a USB-C port, so they’re still widely considered a first-generation product. 

    Any HomePod products

    Apple has a couple of these in the works, including a HomePad smart home hub and the HomePod mini 2. It’s improbable that we’ll see either at the September Apple event, although not impossible. Apple is expected to release the HomePod mini and a new Apple TV 4K device by the end of 2025, and they’re small enough products that they may sneak into the iPhone event. However, it’s more likely that Apple will announce these at a separate event along with the new Macs. 

    The HomePod smart home hub may have to wait even longer for a launch date. Reports claim that Apple has delayed its Google Nest Hub competitor until 2026. Initially, the launch was pushed back to the end of 2025, but more recent reports indicate that Apple wants to wait until 2026 to better prepare Apple Intelligence. So, it’s unlikely that we’ll see any HomePod products on September 9.

    The next Apple Vision Pro

    Rumors about the Apple Vision Pro have been ramping up in recent months as Apple aims to release a refreshed model of the Vision Pro before the end of 2025. This refresh will include the M5 chip and improved comfort. That coincides with the upcoming VisionOS 26 update, which should be released in autumn 2025. Apple is reportedly also working on the Vision Air, but we don’t think that’s coming until 2027 at the earliest. 

    It is highly unlikely that this piece of tech will launch with the iPhone lineup. Since the refresh is coming with an M5 chip, it’s much more likely that it’ll launch with the rest of the M5 products that Apple has coming down the pipeline. Since those aren’t launching with the iPhone, we’ll likely see the refreshed Vision Pro later in 2025. 

    Still, if we’re lucky, Apple may tease some of these products next week.

    The launch event is mostly about the mobile stuff

    Apple usually keeps its products grouped up, and as we said earlier, the iPhone event usually only includes the iPhone, Apple Watch, and AirPods products (and this year, probably the AirTag 2). So, if it’s not in the mobile product category, chances are that you won’t see it launch next week.


    Continue Reading

  • Mis-issued certificates for 1.1.1.1 DNS service pose a threat to the Internet

    Mis-issued certificates for 1.1.1.1 DNS service pose a threat to the Internet

    It wasn’t immediately known which organization or person requested and obtained the credentials. Representatives from Fina, didn’t answer emails seeking details.

    The certificates are a key part of the Transport Layer Security protocol. They bind a specific domain to a public key. The certificate authority, the entity authorized to issue browser-trusted certificates, possesses the private key certifying that the certificate is valid. Anyone in possession of a TLS certificate can cryptographically impersonate the domain for which it was issued.

    The holder of the 1.1.1.1 certificates could potentially use them in active adversary-in-the-middle attacks that intercept communications passing between end users and the Cloudflare DNS service, Ryan Hurst, CEO of Peculiar Ventures and a TLS and public key infrastructure expert, told Ars.

    From there, attackers with possession of the 1.1.1.1 certificates could decrypt, view, and tamper with traffic from the Cloudflare DNS service, Hurst said.

    Castles made of sand

    Wednesday’s discovery exposes a key weakness of the public key infrastructure that’s responsible for ensuring trust of the entire Internet. Despite being the only thing ensuring that gmail.com, bankofamerica.com or any other website is controlled by the entity claiming ownership, the entire system can collapse with a single point of failure.

    Cloudflare’s statement observed:

    The CA ecosystem is a castle with many doors: the failure of one CA can cause the security of the whole castle to be compromised. CA misbehavior, whether intentional or not, poses a persistent and significant concern for Cloudflare. From the start, Cloudflare has helped develop and run Certificate Transparency that has allowed this mis-issuance to come to light.

    The incident also reflects poorly on Microsoft for failing to proactively catch the mis-issued certificates and allowing Windows to trust them for such a long period of time. Certificate Transparency, a site that catalogues in real time the issuance of all browser-trusted certificates, can be searched automatically. The entire purpose of the logs is so stakeholders can quickly identify mis-issued certificates before they can be actively used. The mis-issuance in this case is easy to spot because the IP addresses used to confirm the party applying for the certificates had control of the domain was 1.1.1.1 itself.

    The public discovery of the certificates four months after the fact suggests the transparency logs didn’t receive the attention they were intended to get. It’s unclear how so many different parties could miss the certificates for such a long time span.

    This story was updated to correct an explanation of TLS certificates and to report newly available details.

    Continue Reading

  • Regardless of Kidney Function, Abelacimab Consistently Reduced Bleeding Risk in Patients With AF

    Regardless of Kidney Function, Abelacimab Consistently Reduced Bleeding Risk in Patients With AF

    Regardless of patients’ kidney function, abelacimab (Anthos Therapeutics) had consistently reduced the risk of bleeding compared with rivaroxaban (Xarelto; Bayer HealthCare; Johnson & Johnson), wrote investigators of the AZALEA-TIMI 71 clinical trial (NCT04755283). The findings, which were published in JAMA Cardiology, suggested that abelacimab might offer a notably favorable safety profile, especially among those with chronic kidney disease (CKD), but larger studies are needed.1,2

    Image credit: NanSan | stock.adobe.com

    About the Trial

    Trial Name: Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation (AZALEA-TIMI 71)

    ClinicalTrials.gov ID: NCT04755283

    Sponsor: Anthos Therapeutics, Inc.

    Completion Date (Estimated): December 29, 2028

    CKD is a common disease present in patients with atrial fibrillation (AF) and is often associated with higher rates of bleeding with anticoagulation, explained the authors. Although direct oral anticoagulants (DOACs) are safer than vitamin K antagonists (VKAs) regarding bleeding across a range of kidney function, bleeding risk with DOACs in those with impaired kidney function remains a considerable risk.1

    The authors explain that factor XI (FXI) inhibitors are an experimental class of anticoagulants that cause less bleeding than DOACs. Abelacimab, a novel FXI inhibitor, is a monoclonal antibody without renal elimination, whereas about one-third of rivaroxaban is directly renally excreted. In the multicenter, randomized, active-controlled phase 2b AZALEA-TIMI 71 trial, the investigators evaluated the safety and tolerability of 2 blinded doses of abelacimab compared with open-label rivaroxaban in patients with AF who had a range of kidney function.1,2

    The trial enrolled 1284 patients aged 55 years and older (median age: 74 years) with AF and a CHA₂DS₂VASc score of 4 or higher, or 3 or higher for those with planned concomitant antiplatelet use or creatinine clearance (CrCl) of 50 mL/min or less, who were randomly assigned to receive either 150 mg or 90 mg of abelacimab administered subcutaneously monthly or to rivaroxaban daily. Patients with a CrCl less than 15 mL/min or receiving dialysis were not eligible for enrollment.1,2

    The primary end point for this analysis was International Society on Thrombosis and Haemostasis (ISTH) major or clinically relevant or nonmajor (CRNM) bleeding. Other outcomes for this analysis included ISTH major bleeding alone and a broader bleeding composite of ISTH major, CRNM bleeding, or minor bleeding. Further, exploratory efficacy outcomes—including stroke or systemic embolism and a net clinical outcome composite of ischemic stroke, systemic embolism, major or CRNM bleeding, or death—were also evaluated. Outcomes were prospectively captured during trial follow-up and adjudicated by an independent clinical events committee who were blinded to treatment assignment.1,2

    The findings demonstrated that, in the rivaroxaban group, patients with a CrCl of 50 mL/min or less experienced higher rates of major or CRNM bleeding compared with those with a CrCl greater than 50 mL/min despite dose reduction (incidence rates: 13.6 vs 7.0/100 person-years). Additionally, abelacimab reduced major or CRNM bleeding compared with rivaroxaban regardless of CrCl (CrCl ≤50 mL/min: hazard ratio [HR], 0.26 [95% CI, 0.12–0.54]; >50 mL/min: HR, 0.40 [95% CI, 0.26–0.62]; P value for interaction = .33), with absolute risk reductions of about 10.1 and 4.2 per 100 person-years in those with CrCl of 50 mL/min or less and greater than 50 mL/min, respectively (P value for interaction = .09).1

    This risk reduction was consistent for major bleeding alone and for a broader composite inclusive of major, CRNM, and minor bleeding, wrote the study authors. Notably, results were similar when comparing the individual abelacimab doses to rivaroxaban.1

    “[Limitations include] AZALEA-TIMI 71[’s design] to assess the bleeding profile of abelacimab relative to rivaroxaban; larger studies are necessary to examine the efficacy of abelacimab for stroke prevention. Each of the 4 approved DOACs for AF have variable renal elimination and may differ in their bleeding profiles; thus, our results may not be generalizable to other DOACs,” wrote the study authors. “In this secondary analysis of the AZALEA-TIMI 71 randomized clinical trial, abelacimab consistently reduced the risk of bleeding compared with rivaroxaban across a range of kidney function and irrespective of rivaroxaban dose reduction among patients with AF; however, further data are necessary to evaluate the efficacy of abelacimab for stroke prevention in AF.”1

    REFERENCES
    1. Patel SM, Giugliano RP, Morrow DA, et al. Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial. JAMA Cardiol. Published online September 01, 2025. doi:10.1001/jamacardio.2025.3393
    2. Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation (AZALEA-TIMI 71). ClinicalTrials.gov identifier: NCT04755283. Updated September 2, 2025. Accessed September 3, 2025. https://clinicaltrials.gov/study/NCT04755283

    Continue Reading

  • Apple’s AI Future | The Motley Fool

    Apple’s AI Future | The Motley Fool

    Elon Musk’s xAI has sued Apple over its App Store practices, but the bigger news may be Apple considering acquiring some major AI start-ups. We also cover the government’s interest in taking equity stakes in defense companies and Fox’s weak hand as it looks for higher cable fees.

    In this podcast, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren discuss:

    • Elon Musk suing Apple.
    • Apple’s AI future with Siri and potential acquisitions.
    • The government’s Intel stake and (potential) defense deals.
    • Fox vs. YouTube TV.

    To catch full episodes of all The Motley Fool’s free podcasts, check out our podcast center. When you’re ready to invest, check out this top 10 list of stocks to buy.

    A full transcript is below.

    This podcast was recorded on August 27, 2025.

    Travis Hoium: Is the government going to take a stake in Intel? Motley Fool Money starts now. Welcome to Motley Fool Money. I'm Travis Hoium joined by Lou Whiteman and Rachel Warren. Today we are going to talk about the government potentially taking a stake in Intel, Fox fighting with YouTube. But we're going to start with Elon Musk and Apple. Elon Musk can't seem to stay out of the news for long in this time because he's suing Apple, claiming they're preferencing OpenAI over Grok. Rachel, is this a big deal here? It seems like Elon Musk has to sue everybody in the AI world? Is he just trying to promote Grok? Is there a there with Apple preferencing OpenAI and ChatGPT?

    Rachel Warren: Honestly, I think I want to start with this. For Apple investors like myself, I think this is a nothing burger. We know that Apple has not been the AI growth play that maybe some investors had hoped. I do not think that AI is the reason you invest in Apple at this juncture, in my opinion. I do think it's partnership with OpenAI makes sense. I mean, we know that Apple has been falling behind in the generative AI race, and we've been hearing for a long time now them talking about using third party models to bring Siri's capabilities forward closer to competitors and really update it for the next generation of users. But I want to talk a little bit about the details of what's happening here with this lawsuit. Musk's xAI is suing Apple and OpenAI in Texas. Musk is alleging that the partnership to integrate ChatGPT into Siri, as well as Apple's writing tools, that it stifles competition. He's alleging that it harms the public interest, that it gives OpenAI on unfair advantage by providing access to billions of user prompts from iPhones. The lawsuit also targets OpenAI for allegedly betraying their non-profit mission. You know, remember, Musk co-founded OpenAI with Sam Altman back in 2015, and OpenAI has actually said in the past that Musk wanted OpenAI to be a for profit entity and that he was actually pushing for, control over the company and a majority equity stake for that for profit structure, and then later changed his mind. for its part, Grok continues to be embroiled in its fair share of controversies. I do think that there is a point to be made. OpenAI retains major control of the LLM space, but Grok has some systemic engineering failures from what we can tell that have made it a far less attractive option for tech companies than OpenAI. This is a nothing burger for now.

    Lou Whiteman: To be fair here. Elon isn't the first to say that Apple's putting fingers on the scales for the app store. This is something we've heard before. But that to me is the not interesting part of this complaint. The complaint goes far beyond the App Store. Quite frankly, it sounds like a rant, not a lawsuit. Elon's complaining that Apple and AI are basically so afraid of this Grok super app that's the reason he bought Twitter and the reason he did all this, that that super app is going to just destroy our need for a smartphone that they are conspiring to keep Grok down.

    Travis Hoium: Couldn't it just be the case, Lou, that people prefer ChatGPT to Grok? Wouldn't that come out in discovery? That's the weird thing here is he's opening account warns that the answer may not be good for Grok and for X.

    Lou Whiteman: There's good reason. A, OpenAI was the first out there. If there is a verb in this space, it's ChatGPT, so they have just that incumbent advantage with better name recognition. Also, Rachel hinted this Grok has had some, should we say, very well publicized less than ideal outcomes, which I do think me as a consumer, makes me a little weary of using Grok. I think there are legitimate reasons why it may not be top of the charts right here. Bigger issue for me here, and I think that it's what's going underneath there is, what is the difference between OpenAI and Grok and Gemini and all that. It might be a matter of having that placement and the apps are important because I think, I worry with these companies that we are getting to a point where if this AI works the way it should and it seems to be moving in that direction, what's going to be the difference between them? What's going to be something that compels you to buy one other than the other? How do they differentiate themselves? In that world, where you are in the app store rankings really matter. I think that if Elon is showing his cards, maybe that's what he's admitting that we're heading toward maybe commoditization?

    Travis Hoium: Then it becomes a distribution game. Then I think you do start to, yes app store ranking matters, but it also matters what you're integrated with. You mentioned Gemini. Gemini has announcements seemingly every day with all new companies, so they do have good models. They obviously Google has a huge Cloud service. But if Gemini is going to be integrated into Google Docs and YouTube and Mail and Android, these are going to be huge advantages for a company like that. Grok is trying to ride X, but X is still Lou a pretty small social media service. This is not Meta with billions of users. This is a couple hundred million users. I think you and I are very active, but there's not a lot of us out there. It is a pretty limited business. If that's your distribution model, there are going to be bigger players out there.

    Lou Whiteman: There is, of course, the Tesla question too, right now, and we'll see how long it takes. But there's just a lot going on behind the scenes with Grok. Like you said, Elon likes to sue people. I'll be curious what becomes of this, but it does feel like, to me, again, just frustration with market share in a world where, as you say, distribution, market share, eyeballs might be the differentiator, not the tech.

    Travis Hoium: Other big news item for the week in this space with these companies in particular is Apple potentially looking at buying Mistral and Perplexity. That has been the rumor recently. Reports have surfaced that Gemini could eventually power Siri. That's coming from Google. Apple has not gotten their AI strategy right so far. Siri is something that's been out for what a decade now. Rachel, is Apple coming at this from a desperate position, or are they playing 40 chess and letting the market play out before they make a big move, which is what they did with the iPhone.

    Rachel Warren: I do think that their strategy as an AI play has not been fully coherent so far. I do think that this is still a company that at its core, this is a smartphone, hardware focused business. You're not investing in Apple because of its AI prowess at this point. I do think that's been a disappointment for some investors. I think there are a lot of people who have watched the different AI related announcements Apple's made in the last few years and had hoped for more right now. For me as a shareholder, the thesis still holds for me about this business. This is a tech leader with a very powerful, sticky ecosystem that drives user loyalty. We continue to see really strong growth in other services like it's asset light services business. But the acquisition of a company like Perplexity, for example, Perplexity has an advanced AI powered search engine and natural language capabilities that could really boost Apple properties like Siri, and that could really improve as well their AI platform and user experience. Apple also receives billions annually for Google to be the default search engine on its devices, and acquiring Perplexity could provide something of a homegrown alternative and a strategic fallback if they were to have their current deal disrupted by, say the antitrust lawsuits facing Alphabet's Google now. I don't think there's any secret that Apple has been perceived as trailing rivals like Alphabet, Meta, and Microsoft and the AI space. I think that's a reality that they are contending with. Acquisitions would certainly be a bold strategy to try to catch up and provide a more significant AI platform. They could attract more developers and users and really keep them within the Apple ecosystem. One other thing that I think is important to note, CEO Tim Cook has really positioned Apple's commitment to consumer privacy as a core value for the business under his tenure, and that really creates a need for near perfect accuracy in consumer facing applications. I think that's also underscored some hesitancy to release what could be potentially imperfect AI features. They have a long road to go where this is concerned. Perhaps a series of acquisitions could be the best route for them.

    Travis Hoium: Lou is acquiring your way into this business going to be even feasible? These are huge companies, but it may be the only way for Apple to go.

    Lou Whiteman: First of all, I don't want to rewrite history here. I'm had it with this four dimensional tress thing. Yes, they did it with the iPhone, but Apple we can't give them a pass. They tried, they spent a lot of money and they failed in developing their own AI. To date.

    Travis Hoium: By the way, a lot of the people that have been hired by Meta in particular over the past couple of months used to work at Apple.

    Lou Whiteman: We'll see if that's good or bad. But look, let's not rewrite history. They tried. That said, I don't know if they need to have spent all that money. I don't even know if they need to buy something big. Back to my commoditization talk from before, I believe in AI and I believe it is going to change things. But I believe that there are a number of companies that are spending a really big sum of money to get it right. I don't know if Apple needs to be one of them. Just as with search, Apple owns the customer. I talked about before, distribution might be what matters. I think what Apple has, the customer, that will end up being more important than owning the AI. We know for years Google spent billions to have its search attached to the iPhone. I think we could have a similar world here. I think Apple's definition of winning here is different than the others. Apple's definition of winning is AI boosts iPhone sales and causes a generation of upgrades. They are well positioned to do that right now, despite their failures, despite not having bought any one. I think both, yes, they failed, and they'll be just fine.

    Travis Hoium: The bigger risk is going to be if there is some new hardware paradigm, which we don't yet see in artificial intelligence, so we'll see how that plays out. Next up, we're going to talk about the government potentially taking a stake in not only Intel, but defense companies you're listening to Motley Fool Money.

    Welcome back to Motley Fool Money. One of the big news items on the market over the past week has been the US government agreeing to take a stake in Intel. Intel actually announced this, but the Trump administration floated the idea a couple of weeks ago. It seems like there's at least an agreement in place, Lou, what do we know? Why is this a groundbreaking agreement between the government and a private company?

    Lou Whiteman: I love you saying that they agreed to. There's a lot going on here, and is it groundbreaking? We've seen this before, like in the great financial crisis. The thing that's weird here is that it's going back and rewriting history 'cause this is all tied to the Chips Act, and the Chips Act is already law. Under the Chips Act, Intel got grants and loans, and we're basically now just after the fact saying, actually we want equity instead. It's problematic in a way.

    Travis Hoium: For Intel, they're not getting any more money than they previously were?

    Lou Whiteman: No.

    Travis Hoium: What's the advantage for Intel?

    Lou Whiteman: The advantage to Intel is it gets the government off their back. I think if we're honest. That's why it's problematic to me because look, if Intel was on its way to hitting the milestones needed to earn these grants, then it's the government going back on its word. If they weren't it feels like new legislation would be needed to change the terms. We didn't see any of this. I will say that I'd be more worried if they did this without the cover of the Chips Act because I think with the Chips Act is actually, at least we can say this is normal. This isn't just randomly going out and taking a stake in a company. But it does add another layer of uncertainty. Intel holders were just deluded by 10% overnight. As a stock investor, I don't want to see this become common practice. I don't think we're there yet, but I'm at least weirded out by it.

    Travis Hoium: Rachel, what was your takeaway?

    Rachel Warren: There's a lot to unpack here. As Lou alluded to, this deal with Intel essentially converted about $9 billion in federal grants into an equity stake. We also had comments the other day from Commerce Secretary Howard Lutnick, which confirmed that the administration is considering taking equity stakes in defense contractors like Lockheed Martin. You know, there's some major concerns I have on these fronts, but we're here to unpack really the investment angle. I will focus on that. The government's significant stake in Intel or other companies if that happens in the coming weeks and months, it does minimize the influence of existing shareholders. Speaking to Intel specifically, government involvement could shift Intel's focus from, say, pure profit driven goals to more national security driven objectives. You could also see an environment where a government stake subjects Intel to new or additional regulations and restrictions in other countries. Intel's own filing notes that the government stake could deter third parties from engaging with the company in some cases, and that could obviously potentially affect future financing and strategic partnerships. Of course, probably one of the most obvious concerns here is that the government's interests, whether it pertains to national security or economic policy, might not always align with the financial interests of private shareholders. It could mark a move toward a more state engaged economy. It is a significant change from a purely capitalist model, and one has to wonder, could this set a precedent for future government intervention in private industries? That would alter corporate governance models.

    Travis Hoium: That remains to be other big takeaway here, there's some intel specific parts about this deal. Lou, you mentioned that with the Chips Act. But the idea of taking a stake in defense companies that don't have the same funding and grants behind them, that could be really a game changer for these companies, the way that we think about them as investments. Hat can of worms are we opening up here, Lou?

    Lou Whiteman: This scares me, and I should say that part and parcel for the defense contractors is, please the customer. That's how this industry works. I've long argued that the defense contractor, their core competency is understanding how the government works better than most companies. There is an instinct, if asked to do it. You could easily see almost a pay for play world, like we just had the Boeing, Lockheed bake off for a new fighter jet. What if there's a world where one of those companies said, not only will we offer you this price, but we'll give you a 10% stake? As an investor, that is not a path I want to go down. I'm hoping cooler heads will prevail. I don't think there's much of a case for them coming in after the fact, saying we're going to take stakes. I think that that would get into litigation. You wouldn't have the cover of the Chips Act, but we really need to think through where we're going here because it would honestly for me, change the dynamics of potentially investing in these companies if that is part of the bid process.

    Travis Hoium: No doubt the courts are going to weigh in here, so a lot to come, but this is a new piece of the investing world that we'll have to deal with. When we come back, we're going to talk about the latest battle in TV in the future of streaming you're listening to Motley Fool Money.

    Welcome back to Motley Fool Money. Now, every media company is trying to build their own streaming app, and Fox is no different, but they're a little later than most. The company recently launched Fox One, which is the stand-alone property. But they have also picked a fight with YouTube TV, one of the biggest virtual cable companies. Ahead of the football season, Fox may not be on YouTube TV. Lou, is this a big deal, and is Fox playing a hand that is even worth playing at?

    Lou Whiteman: Yes. They are playing the football hand. It's the oldest card in the book. America loves its football, so this is when they have leverage. I'll say, as a YouTube subscriber who's not really into it, YouTube's offered ten bucks back if it doesn't come through. I'm rooting for that, Travis, but I know I'm in the minority here. I think YouTube for that reason that we we want our football and so they have to have it. But I'll tell you, I do think I'm ready to move past these dramas. I'm afraid that what comes next is worse. You have the ESPN stand-alone with ABC. Fox has the stand-alone. Peacock, Paramount gets the NBC and CBS. All the networks are covered as a consumer, we're heading toward the most terrible future where paying separately for everything, having to leave an app and go into an app just to change the channel. I'm going to hate this. We Roku. Everybody needs to rethink things. But I do think that this is just the old try and true playbook and it'll probably work as it always does, and I'll just end up paying more.

    Travis Hoium: This is one of those situations where we've now started to do the math on Is it worth canceling YouTube TV and just subscribing to every single one of these apps.

    Lou Whiteman: Let me know because I'm going to do that, but I'm too lazy. Let me know.

    Travis Hoium: Rachel, what's the future here for Fox in particular? Because they do have football. They do have their own streaming service, but Fox News and football is a strange combo in a world where the alternatives seem more compelling.

    Rachel Warren: I think in the short term, looking at it from a consumer perspective and investment perspective, YouTube probably is going to cave. I do agree with Lou on that front. But I think as you look over the long term and you look at these different platforms, I think YouTube and YouTube TV remain supreme, you think about how YouTube, including its live TV service, captures the largest share of total TV viewing in the US. It consistently holds the top spot and has for the last six consecutive months as of August 2025, that's based on reports from Nielsen ratings. It's the largest contributor to overall streaming growth. It's a formidable player in the market. Obviously, Fox has some major cards to play. If its channels are removed, you know, from YouTube, that could happen by end of day today if a deal is not reached from this carriage dispute. But looking at it as an investor in a company like Alphabet, as I'm, it's also the case that platforms like YouTube are fundamentally changing the business model of entertainment and content creation, and that is a reality that is not going anywhere.

    Travis Hoium: I don't know if Fox versus YouTube is going to be really a fair fight, but we'll see how much power football has here. As always, people on the program may have interest in the stocks they talk about and the Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. All personal finance content follows Motley Fool's editorial standards. It is not approved by advertisers. Advertisements are sponsored content and provided for informational purposes only. To see our full advertising disclosure, please check out our show notes. For Lou Whiteman, Rachel Warren, and our production magician Bart Shannon the entire Motley Fool team, I'm Travis Hoium. Thanks for listening to Motley Fool Money. We'll see you here tomorrow.


    Continue Reading

  • Newsmax sues Fox News in battle of right-wing TV networks

    Newsmax sues Fox News in battle of right-wing TV networks

    Right-wing US media network Newsmax is suing Fox News over what it claims are anticompetitive tactics to supress competition, teeing up a legal battle in the American conservative news space.

    The lawsuit, filed in a Florida federal court, accuses Fox News of using its market power to coerce TV providers to restrict competing right-leaning channels.

    “Newsmax cannot sue their way out of their own competitive failures in the marketplace to chase headlines simply because they can’t attract viewers,” a Fox News spokesperson said.

    The company, owned by billionaire Rupert Murdoch, is consistently ranked the most popular conservative news outlet in the US with a market value of nearly $26bn (£19bn).

    Fox News “has long engaged in an exclusionary scheme to increase and maintain its dominance in the market for US right-leaning pay TV news,” lawyers for Newsmax wrote in its antitrust complaint.

    It’s alleged Fox News uses exclusive content deals to block other right-wing channels, and imposes financial penalties on providers that do carry other conservative networks, among other exclusionary tactics.

    The suit also accuses Fox News of using intimidation including pressuring its guests to not appear on rival networks, and hiring private investigators to target Newsmax executives

    “Fox may have profited from exclusionary contracts and intimidation tactics for years, but those days are over,” Newsmax CEO Christopher Ruddy said.

    It’s asking a judge to declare Fox News’ conduct unlawful, and block it from entering into what it says are exclusionary contracts, in addition to monetary damages.

    Newsmax, founded in 1998 with a market value of $1.8bn, has gained traction in recent years, buoyed by support from President Donald Trump.

    The company had its own legal woes in the wake of Joe Biden’s 2020 election victory over Trump.

    Newsmax agreed to pay $67m (£50m) to settle a defamation lawsuit filed by a voting machine company over false claims it rigged the election.

    Dominion, which filed the case in 2021, had accused Newsmax of broadcasting “verifiably false lies”.

    Fox News was also embroiled in litigation with Dominion, agreeing to settle a $787.5m (£634m) lawsuit following the election.

    Continue Reading

  • Apple Watch Ultra 3: Rumored specs, pricing, and battery life

    Apple Watch Ultra 3: Rumored specs, pricing, and battery life

    At the time of writing, Apple’s big iPhone event is just around the corner — a week away, give or take, depending on when you’re reading this. And while most of the hype is centered on the iPhone 17 and the new Liquid Glass UI coming with iOS 26, the Apple Watch will also be a supporting player during the big show.

    In fact, we’re expecting to see three new smartwatches make their debut at the Apple event on Sept. 9 — the Apple Watch Series 11, the Apple Watch SE, and the Apple Watch Ultra 3.

    Not to sound like a broken record, but as with the iPhone 17 (and the Series 11), we’re expecting incremental upgrades, not a drastic redesign. That’s not to say we won’t see anything new, but temper your expectations for the $800 smartwatch. Here’s everything we know so far, and everything we think we know.

    SEE ALSO:

    3 features we hope Apple brings to the iPhone 17

    Apple Watch Ultra 3: Price

    Let’s start with the good news: As hinted above, the Ultra 3 is expected to stick to last year’s $799 starting price. That’s still a steep buy-in, even for Apple’s top-tier wearable, but in the tariffs era, a lot of products are getting more expensive.

    Like the Series 11 and iPhone 17, we think the Ultra 3 will be announced on Sept. 9, with preorders likely kicking off around Sept. 12. Early adopters can have it on their wrists as early as Sept. 19.

    Mashable Light Speed

    Apple Watch Ultra 3: Design and Display

    According to MacRumors, the Ultra 3 is expected to sport a larger display — roughly 10 percent bigger than the Ultra 2. Measuring in at 2.12 inches, the new screen may also mark a shift away from OLED, with Apple reportedly testing more energy-efficient options like microLED or wide-angle LTPO panels.

    There are also rumblings of an onboard camera, a feature that popped up in our Series 11 rumor roundup as well. If it makes the cut this year, the camera would sit on the side of the case near the digital crown. Don’t expect it to replace your iPhone, though. As Bloomberg’s Mark Gurman notes, the feature would likely serve more for AI-driven visual analysis than snapping Instagram-ready photos.

    Apple Watch Ultra 3: Hardware

    A new Ultra also means a new chip. After two years, the Ultra 3 will finally get an upgrade with Apple’s latest S11 processor. The Ultra 2 ran on the S9, while the Series 10 jumped to an S10, but this year Apple is aligning the lineup — the Series 11, Ultra 3, and the rumored SE 3 are all rumored to ship with the updated S11.

    That said, don’t get your hopes up too high. While it’s technically a new processor, MacRumors reports that leaks suggest the S11 shares much of the same internal architecture as the S9 and S10. It’s still a solid chip for a smartwatch, but in terms of real-world performance, the gains are expected to be modest at best.

    The Ultra 3 is also expected to feature a larger charging coil, which should help extend battery life. Combined with the new energy-efficient display, CNET reports that the watch could last up to 72 hours in low power mode — a major boost for adventurers and endurance users.

    Apple Watch Ultra 3: New watchOS 26 features

    One of the standout upgrades, according to Mark Gurman, will be satellite messaging. The Ultra 3 is tipped to be the first Apple wearable capable of dispatching emergency texts via the Globalstar satellite network. That means even if you’re completely off the grid without cell service, you could still get a lifeline out. (Garmin recently announced its own flagship smartwatch with satellite connectivity, set to be released Sept. 8, the day before the Apple event.)

    There are also rumors of built-in blood pressure monitoring, a feature that could provide early warnings for users at risk of hypertension. Beyond that, expect the Ultra 3 to carry over much of what the Ultra 2 already offered — with the notable addition of 5G connectivity baked directly into the watch.

    Continue Reading

  • Early Breast Cancer Survivors Face Only Slight Second Cancer Risk – Inside Precision Medicine

    1. Early Breast Cancer Survivors Face Only Slight Second Cancer Risk  Inside Precision Medicine
    2. Study Shows That After Early Breast Cancer Diagnosis, Risk of a Second Cancer is Low  The ASCO Post
    3. Breast cancer survivors’ cancer risk lower than thought – study  BBC
    4. Long-Term Study Offers Reassurance to Early Breast Cancer Survivors  HealthDay
    5. Breast Cancer Survivors Face Modest Second Cancer Risk  Medscape

    Continue Reading

  • 'Ketamine Queen' pleads guilty in 'Friends' star Matthew Perry's drug death – Reuters

    1. ‘Ketamine Queen’ pleads guilty in ‘Friends’ star Matthew Perry’s drug death  Reuters
    2. ‘Ketamine Queen’ pleads guilty in Matthew Perry overdose case  BBC
    3. ‘Ketamine Queen’ pleads guilty in Matthew Perry’s overdose death  NBC News
    4. ‘Ketamine Queen’ pleads guilty to selling drugs to Matthew Perry that led to the ‘Friends’ star’s fatal overdose  Rocky Mount Telegram
    5. CA high-speed rail  LAist

    Continue Reading

  • AI Support for Blood Cancer Patients Limited to General Questions – Inside Precision Medicine

    1. AI Support for Blood Cancer Patients Limited to General Questions  Inside Precision Medicine
    2. STUDY: Evaluating Chatbot Accuracy in the Fast-Changing Blood Cancer Field  southfloridahospitalnews.com
    3. Study Evaluates ChatGPT’s Accuracy in Answering Blood Cancer Medical Questions  geneonline.com
    4. Study Evaluates ChatGPT’s Accuracy in Answering Blood Cancer Medical Queries  geneonline.com

    Continue Reading

  • 5 money moves to make if you win the $1.4 billion Powerball jackpot tonight – or get a similar financial windfall – Morningstar

    5 money moves to make if you win the $1.4 billion Powerball jackpot tonight – or get a similar financial windfall – Morningstar

    1. 5 money moves to make if you win the $1.4 billion Powerball jackpot tonight – or get a similar financial windfall  Morningstar
    2. Why haven’t we seen a massive Powerball, Mega Millions jackpot recently?  WGN-TV
    3. Powerball jackpot increased to $1.40 billion ahead of tonight’s drawing  Powerball
    4. Winning $1 million Powerball ticket sold at Manassas Wawa; $1.4 billion drawing tonight  insidenova.com
    5. Hundreds rush to grab free Powerball tickets in Chicago ahead of $1.4B drawing  MSN

    Continue Reading